Aktuelle Drittmittelförderung

TitelInstitutionFKZLaufzeitPI
Proteotoxicity: an unappreicated mechanism of heart disease and its potential for novel therapeuticsFondation Leducq11CVD042011 - 2016Carrier
Hypertrophic cardiomyopathy: from gene identification to individualized therapyBMBF81Z/27101022011 - 2018Carrier
EU Training Network on Novel Targets and Methods in Atrial Fibrillation - AFib-TrainNetEuropean Commission6753512015 - 2019Christ
S-Glutathionylierung von kardiaöem Myosi-bindendem Protein C bei kontraktiler DysfunktionDFGCU 53/2-12014 - 2017Cuello
Oxidative post-translationale Modifikation bei kardiovaskuläreren ErkrankungenBMBF81Z/27101062015 - 2018Cuello
CVRC Echo Core facilityBMBF81Z/77101012011 - 2018Eschenhagen
Biodesign-Rational Bioactive Materials Design for Tissue RegenerationEuropean Commission
2629482012 - 2016Eschenhagen
Imperial College BHF Centre for Cardiac Regeneration: Four year research programmeBritish Heart FoundationRM/13/1/301572013 - 2017Eschenhagen
Engineered 20 & 3D hipsc-CM platforms to detect cardiovascular safety liabilitiesNational Centre for the Replacement, Refinement and Reduction of Animals in ResearchCRACK IT - 35911-2591462014 - 2017Eschenhagen
IndivuHeart - Individualized early risk assessment for heart diseasesEuropean Research Council3402482014 - 2019Eschenhagen
Der EHT-Chip – Screening künstlicher Herzmuskelgewebe im Mikro-FormatBehörde für Wissenschaft und Forschung HamburgE43026-032015 - 2017Eschenhagen/Trieu
Electromechanical dyssynchrony and resynchronization; New cellular and molecular insight using in-vivo and in-vitro rat modelsGerman-Israeli Foundation for Scientific Research and DevelopmentI-1300-201.14/20152016 - 2018Eschenhagen/Etzion
Cardiac tissue engineeringBMBF81Z/27101012011 - 2018Eschenhagen/Hansen
Understanding the causes of heart defects in myotonic dystrophies - HEART DME-Rare / BMBF01GM13052013 - 2017Hansen